NAS (Neonatal Abstinence)
Finnegan Neonatal Abstinence Score for assessing neonatal withdrawal symptoms
The Neonatal Abstinence Syndrome (NAS) score quantifies withdrawal symptoms in opioid-exposed newborns to guide timing and intensity of pharmacologic treatment. Based on clinical observations of withdrawal manifestations including irritability, sleep disturbances, feeding difficulties, and gastrointestinal symptoms, this tool helps standardize assessments across the first weeks of life. Use this scoring system in all term and late preterm (≥35 weeks) infants with perinatal opioid exposure to determine whether treatment is needed and monitor response to therapy.
Clinically Verified· 5 testsFor educational and informational purposes only. Verify all results before clinical application.
References
- Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2(1-2):141-158.
- Grossman MR, et al. An Initiative to Improve the Quality of Care of Infants With Neonatal Abstinence Syndrome. Pediatrics. 2017;139(6):e20163360.[DOI]
Reviewed by Daniel Diaz-Gil, MD · Last updated March 2026
Medical disclaimer
This tool is for educational and informational purposes only. It is not a substitute for professional clinical judgment. Always independently verify results before making clinical decisions.